View Press Releases

Multi-Arm PEG Architectures Expand Options for Long-Acting Biologic Development

March 16, 2026

WATERTOWN, MA – Advances in biologics and peptide therapeutics continue to drive innovation in drug delivery and molecular design. Among the enabling technologies supporting these developments, PEGylation remains a widely adopted strategy for improving the pharmacokinetics and stability of therapeutic molecules.

Polyethylene glycol (PEG) conjugation has long been used to enhance solubility, reduce proteolytic degradation, and extend circulation time. In recent years, multi-arm and branched PEG architectures have attracted increasing attention as researchers explore new ways to design long-acting biologics and multifunctional drug conjugates.

Unlike traditional linear PEG chains, multi-arm PEG structures contain several branching points that create a larger hydrodynamic volume and provide multiple functional attachment sites. This architecture can offer advantages in controlling drug exposure, protecting sensitive biomolecules, and enabling more flexible conjugation strategies.

Several approved PEGylated drugs demonstrate how PEG design can influence therapeutic performance. These include Izervay (avacincaptad pegol), Skytrofa (lonapegsomatropin-tcgd), Yorvipath (palopegteriparatide), and Cimzia (certolizumab pegol). Such therapies illustrate the role PEGylation can play in extending half-life and enabling less frequent dosing schedules.

Structural Advantages of Multi-Arm PEG

Researchers increasingly consider multi-arm PEG reagents when designing advanced PEGylated constructs due to several structural characteristics:

  • Larger hydrodynamic size, which can reduce renal filtration and extend systemic circulation
  • Enhanced steric shielding around proteins or peptides, helping improve molecular stability
  • Improved pharmacokinetic control, enabled by tunable molecular weight and branching design
  • Multiple conjugation sites, allowing multivalent constructs or multifunctional drug systems

    These properties make branched PEG structures particularly relevant for the development of long-acting biologics, peptide therapeutics, and complex bioconjugates.

    Supporting PEGylation Research

    Biopharma PEG provides a range of high-purity multi-arm PEG reagents designed to support PEGylation research, conjugation development, and scale-up production.

    The portfolio includes:

    Y-Shaped Branched PEG

    Designed for single-site protein or peptide modification while increasing effective molecular size.

  • Y-shape PEG-NHS (MW 40K, 43K)
  • 2-Arm PEG-Maleimide (MW 10K, 40K, 43K)

    4-Arm and 8-Arm PEG

    Branched PEG reagents that support higher loading capacity and multi-component conjugation strategies.

  • 4-Arm / 8-Arm PEG-SG (MW 2K, 10K, 20K)
  • 4-Arm / 8-Arm PEG-SS (MW 2K, 10K, 20K)
  • 4-Arm / 8-Arm PEG-Maleimide (MW 2K, 10K, 20K)

Custom Multi-Arm PEG

Custom PEG architectures can also be developed to meet specific research needs, including tailored molecular weights, functional groups, and GMP or non-GMP grade materials.

Enabling Drug Development

According to Dr. Deng, scientist at Biopharma PEG, “As biologics become more sophisticated, the design of PEG linkers and architectures becomes increasingly important. Multi-arm PEG structures provide researchers with additional flexibility in controlling pharmacokinetics and conjugation strategies. Our goal is to support scientists and partners in advancing PEGylated therapeutics from early research through drug development.”

With continued interest in long-acting therapeutics and advanced bioconjugation platforms, PEGylation technologies—including multi-arm PEG reagents—are expected to remain a key component of biologic drug design.

Researchers working on PEGylated therapeutics or conjugate drug platforms can request additional technical information from Biopharma PEG regarding available multi-arm PEG reagents and customization options.

About Biopharma PEG

Biopharma PEG is a dynamic biotechnology company headquartered in Watertown, Massachusetts, specializing in the development and manufacturing of high-purity PEG derivatives. The company supports global pharmaceutical and biotech partners with a comprehensive range of PEGylation reagents and custom synthesis services for long-acting biologic development.

Website: https://www.biochempeg.com/ 

Email: sales@biochempeg.com